Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Masini, S; Basa, MA; Calles, A; Cabellos, RA; Echebarria, ID; Puchol, CT; Kareaga, MM; Cabezon-Gutierrez, L; Perez, MCE; Lage, Y; Lorenzo, EG; Navarro, F; Sereno, M; Martínez, SF; García-Benito, C; Pinto, LM; Andrade, CA; Sequero, S; Martinez, JM; Lopez-Martín, A; Martínez, AA; Martín-Soberon, MC; Lucia-Gozalvez, C; Rubio, J; Tallafigo, L; Garrido, A; Peressini, M; Torres-Jimenez, J; Zurera, M; Bote, H; Ponce, S; Paz-Ares, L; Zugazagoitia, J; Baena, J.

Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression = 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study)

Cancers. 2025; 17(22): [doi:10.3390/cancers17223643]

Garcia-Saenz, JA; Lopez-Barajas, IB; Echavarria, I; Gonzalez, CH; Vila, MM; Antón, FM; Pernas, S; Cajal, TRY; Ribelles, N; Ezquerra, MB.

SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025)

Clinical & Translational Oncology. 2025; 28(1): 126-147 Nº de citas: 2 [doi:10.1007/s12094-025-04102-w]

Castet, F; Fabregat-Franco, C; Bridgewater, J; Kim, JW; Rimini, M; La Casta, A; Lamarca, A; Kang, MS; Salani, F; Castillo, A; Lopes, A; Hyung, J; Rimassa, L; Adeva, J; López-Valbuena, D; Basagaña-Farres, M; Vaja, S; Mak, KM; Tian, TV; Muñoz, A; Casadei-Gardini, A; DURVABTC Grp; Yoo, C; Valle, JW; Macarulla, T.

Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer

JOURNAL OF HEPATOLOGY. 2025; 83(5): Nº de citas: 2 [doi:10.1016/j.jhep.2025.05.020]

Lala, M; Bardia, A; Calles, A; Danesi, R; Freshwater, T; Healy, JA; Herbst, RS.

Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis

Targeted Oncology. 2025; 20(6): 955-965 [doi:10.1007/s11523-025-01185-x]

Crown, J; Stroyakovskii, D; Huang, CS; Yardley, DA; Fasching, PA; Bardia, A; Chia, S; Im, SA; Martin, M; Xu, B; Barrios, CH; Untch, M; Moroose, R; Hurvitz, SA; Hortobagyi, GN; Slamon, DJ; Visco, F; Spera, G; Zarate, JP; Halligan, D; Li, Z; Loi, S.

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year followup of NATALEE efficacy outcomes and updated overall survival

ESMO Open. 2025; 10(11): Nº de citas: 13 [doi:10.1016/j.esmoop.2025.105858]

Smith, M; Piulats, J; Todenhöfer, T; Lee, JL; Arija, JA; Mazilu, L; Azad, A; Alonso-Gordoa, T; McGovern, U; Choudhury, A; Horvath, L; Ye, DW; Han, WQ; Suzuki, H; Uemura, H; Mckay, R; Ades, S; Fléchon, A; Pieczonka, C; Fernandes, MS; Hulstijn, M; Lithio, A; Nacerddine, K; Agarwal, N.

Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2) : a randomised, double-blind, placebo-controlled, phase 3 trial

LANCET ONCOLOGY. 2025; 26(11): 1489-1500 Nº de citas: 3 [doi:10.1016/S1470-2045(25)00475-9]

Rosa, AA; Carolina, AP; Marta, AV; Francisco, A; Adriana, FG; Natalia, G; Pablo, LL; Cristina, MF; Lidia, MS; Ulrike, N; Marina, S; Guillermo, HT; Henar, CG; Ana, GOD.

Desmoid Tumors-Experience from a Referral Center, Part 1: Multidisciplinary Review and Practical Recommendations

Cancers. 2025; 17(21): Nº de citas: 3 [doi:10.3390/cancers17213470]

Lopez, BH; Montealegre, MC; Soulas, C; Rufrancos, BA; Cuéllar, MLGO; Millán, MD; Lopez, LV; Cobo, SLT; Gilarranz, YJ; Díaz-Guardamino, IE; Jara, P; Jiménez, MM; Sánchez, TM; Beltrán, MJM; Montero, JCD; Barrio, SC.

Randomized pilot study of an individualized multimodal exercise, nutrition, and behavior intervention in breast cancer patients treated with ovarian function suppression: protocol proposal for The OvS Breast ENBI Project

Frontiers in Oncology. 2025; 15: Nº de citas: 1 [doi:10.3389/fonc.2025.1622622]

Caraballo, IG; Delgado, BL; Zamorano, MR; Salgado, M; Pachón, V; Galán, JM; Castellón, V; Gardeazabal, I; Ferrer, A; Pérez, JR; Escobar, IG; Fernández, I; Quintanar, T; Font, C; Alsar, JS; Morán, LO; Fernández, JMS; Martín, AJM.

Comparative analysis of risk prediction scores including all types of cancer-associated thrombosis

Clinical & Translational Oncology. 2025; : [doi:10.1007/s12094-025-04099-2]

Pacheco-Barcia, V; Mariño-Mendez, A; Hernandez-Jimenez, E; Jimenez-Fonseca, P; Martín, AJM; Custodio-Cabello, S; Palka-Kotlowska, M; Gonzalez-Diaz, I; Cabezon-Gutierrez, L.

Gut microbiome and nutritional strategies in gastrointestinal cancers: Clinical implications and therapeutic perspectives

World Journal of Clinical Oncology. 2025; 16(10): [doi:10.5306/wjco.v16.i10.107877]

Ascierto, PA; Del Vecchio, M; Merelli, B; Gogas, H; Arance, AM; Dalle, S; Cowey, CL; Schenker, M; Gaudy-Marqueste, C; Pigozzo, J; Márquez-Rodas, I; Butler, MO; Di Giacomo, AM; Gligich, O; de la Cruz-merino, L; Arenberger, P; Atkinson, V; Nathan, P; Hill, A; Millward, M; Fecher, LA; Khushalani, NI; Queirolo, P; Soomro, R; Rathod, D; Askelson, M; Benito, MP; Joseph, D; Larkin, J.

Nivolumab for Resected Stage III or IV Melanoma at 9 Years

NEW ENGLAND JOURNAL OF MEDICINE. 2025; 394(4): Nº de citas: 10 [doi:10.1056/NEJMoa2504966]

Li, J; Deng, T; Gu, YH; Blanco, AC; Li, ZH; Bai, CM; Wu, L; Huang, J; Li, XY; Yao, Y; Song, ZB; Li, YS; Liu, L; Xing, LG; Wu, WM; Martinez-Perez, J; Hubert, A; Zugazagoitia, J; Zhang, J; Wang, YS; Zhao, YQ; Wen, GL; Xia, GH; Zhong, DS; Chen, XQ; Jiang, KR; Wang-Gillam, A; Ding, YL; Liu, SM; Rao, ZY; Liu, XH; Shen, L.

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

Cancer Communications. 2025; : Nº de citas: 4 [doi:10.1002/cac2.70056]

Cho, BC; Ahn, MJ; Nishio, M; Murakami, H; Wan-Kim, D; Kim, SW; Karam, SD; Estival, A; Lin, CC; Trigo, JM; Alvarez, R; Wang, CL; Xie, MC; Iyer, S; Armstrong, J; Chugh, P; Jiang, HY; Bauman, JE.

Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study

JTO Clinical and Research Reports. 2025; 6(10): Nº de citas: 1 [doi:10.1016/j.jtocrr.2025.100884]

Lonardi, S; Lugowska, I; O'Donnell, A; Jackson, C; Latten-Jansen, LM; North, R; Bahleda, R; Garrido, M; Santoro, A; Chacon, MR; Li, LH; Joseph, D; Vezina, HE; Aras, U; Bennett, B; Perumal, D; Gurm, B; Ng, WT; Harvey, RD; Trigo, J; Calvo, A.

Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study

Journal for ImmunoTherapy of Cancer. 2025; 13(10): Nº de citas: 1 [doi:10.1136/jitc-2025-011918]

González-del-Alba, A; Ballesteros, CM; Arranz, JA; Gallardo, E; Sarrió, RG; Campos, FL; Muñoz-Rodríguez, J; Méndez-Vidal, MJ; de Iturriaga, AG.

Therapeutic Alliances for Optimizing the Management of Patients with Prostate Cancer: SOGUG Multidisciplinary Expert Panel Recommendations

Cancers. 2025; 17(19): Nº de citas: 1 [doi:10.3390/cancers17193208]

Lobato-Delgado, B; Ruiz, M; Font, C; Pachón, V; Castellón, V; Martinez-Marin, V; Salgado, M; Martinez, E; Calzas, J; Ortega, L; Ruperez, A; Pujol, O; Soria, JM; Muñoz, A.

Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort study

IJC Heart & Vasculature. 2025; 60: Nº de citas: 2 [doi:10.1016/j.ijcha.2025.101754]

Soto-Alsar, J; Revuelta-Herrero, JL; Villanueva-Bueno, C; Cobos-Lama, C; Cañete-Muñoz, MA; Muñoz-Martin, A; Garcia-Alfonso, P; Soto-Alvarez, J.

Budget impact analysis of new drugs in oncology and haematology: Principles and practice

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2025; : Nº de citas: 1 [doi:10.1002/bcp.70303]

Vaz-Salgado, MA; Valverde-Morales, C; Alvarez, R; Asencio, JM; Collado, E; de Alava, E; Beveridge, RD; Gómez-Mateo, MC; Alegria, IG; Marquina, G; Broto, JM; Martínez-Trufero, J; Narváez, JA; Redondo, A; Sebio, A; Verges, R; Viñals, JM; del Muro, XG.

Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines

Cancers. 2025; 17(19): [doi:10.3390/cancers17193158]